Tag: Excel Diagnostics

Clinical Trial Rider Insurance Policy from Golden Rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

READ MORE
Ebrahim S. Delpassand, MD

First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate

November 20, 2012

Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …

READ MORE
Ebrahim S. Delpassand, MD, is the principal investigator for the first PRRT clinicial trial in the United States, a milestone treatment for neuroendocrine cancer.

FDA Approves Amendment for PRRT Clinical Trial in Texas

August 2, 2012

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate

READ MORE
Jan Naritomi-Hart wins 2011 Warner Advocacy Award

10 Highlights of the Year 2011 for the Carcinoid and Neuroendocrine Tumor Community

December 15, 2011

As the Carcinoid Cancer Foundation looks back on the year 2011, there were many significant events and advances for the carcinoid and neuroendocrine tumor (NET) community.  Here are 10 of the year’s important stories:

1)     The FDA approved…

READ MORE
Unicorn Foundation, Australia, celebrates Worldwide NET Cancer Awareness Day 2011

Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America

November 7, 2011

Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on www.netcancerday.org  as the sun travels west, from Australia to Europe to North…

READ MORE
GlucoMedix PET imaging agent

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE
Neuroendocrine Cancer Clinical Trial and PRRT and Ebrahim S. Delpassand

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

August 24, 2010

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate.   Ebrahim S. Delpassand, MD, chief executive officer and medical director…

READ MORE